To determine whether 5-HT1A receptor mediates the anti-IBS-like effects of resveratrol, we observed whether pretreatment of 5-HT1A antagonist NAN-190 (0.1 mg/kg) blocked the effects of resveratrol on PKA, pCREB/CREB and BDNF expression in the hippocampus. Here, CREB1 is linked to irritable bowel syndrome.